Safety and Tolerability of Namisol in the Elderly

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Drug Safety
Interventions
DRUG

delta-9-tetrahydrocannabinol

During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.

DRUG

Placebo

On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study

Trial Locations (1)

Unknown

Radboud University Medical Centre, department of Geriatrics, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT01740960 - Safety and Tolerability of Namisol in the Elderly | Biotech Hunter | Biotech Hunter